Fifth Third Bancorp Sells 26,156 Shares of Thermo Fisher Scientific Inc. $TMO

Key Points

• Fifth Third Bancorp reduced its stake in Thermo Fisher Scientific by 7.5%, selling 26,156 shares during the second quarter, leaving it with approximately 0.09% ownership valued at $130.2 million.
• Thermo Fisher reported earnings of $5.36 per share, exceeding analysts' expectations, with quarterly revenue increasing by 2.9% year-over-year to $10.86 billion.
• The company announced a quarterly dividend of $0.43 per share, resulting in an annualized yield of 0.4%, which will be distributed on October 15th.

Fifth Third Bancorp lessened its position in shares of Thermo Fisher Scientific Inc. (NYSE:TMO - Free Report) by 7.5% in the second quarter, according to the company in its most recent 13F filing with the Securities and Exchange Commission. The firm owned 321,225 shares of the medical research company's stock after selling 26,156 shares during the period. Fifth Third Bancorp owned approximately 0.09% of Thermo Fisher Scientific worth $130,244,000 as of its most recent filing with the Securities and Exchange Commission.

A number of other institutional investors and hedge funds also recently made changes to their positions in the company. CCM Investment Advisers LLC lifted its holdings in shares of Thermo Fisher Scientific by 1.5% during the 2nd quarter. CCM Investment Advisers LLC now owns 31,344 shares of the medical research company's stock worth $12,709,000 after acquiring an additional 449 shares during the period. Sheets Smith Wealth Management lifted its holdings in shares of Thermo Fisher Scientific by 26.8% during the 2nd quarter. Sheets Smith Wealth Management now owns 3,817 shares of the medical research company's stock worth $1,547,000 after acquiring an additional 807 shares during the period. Compagnie Lombard Odier SCmA lifted its stake in Thermo Fisher Scientific by 12.2% in the 2nd quarter. Compagnie Lombard Odier SCmA now owns 280,728 shares of the medical research company's stock valued at $113,824,000 after purchasing an additional 30,461 shares during the last quarter. Unified Investment Management lifted its stake in Thermo Fisher Scientific by 16.9% in the 2nd quarter. Unified Investment Management now owns 968 shares of the medical research company's stock valued at $392,000 after purchasing an additional 140 shares during the last quarter. Finally, Town & Country Bank & Trust CO dba First Bankers Trust CO lifted its stake in Thermo Fisher Scientific by 12.1% in the 2nd quarter. Town & Country Bank & Trust CO dba First Bankers Trust CO now owns 2,539 shares of the medical research company's stock valued at $1,029,000 after purchasing an additional 274 shares during the last quarter. Institutional investors own 89.23% of the company's stock.

Thermo Fisher Scientific Price Performance

TMO stock opened at $469.41 on Wednesday. Thermo Fisher Scientific Inc. has a 52-week low of $385.46 and a 52-week high of $623.77. The company has a fifty day moving average price of $474.01 and a 200-day moving average price of $448.70. The company has a market capitalization of $177.25 billion, a P/E ratio of 27.15, a PEG ratio of 2.54 and a beta of 0.75. The company has a debt-to-equity ratio of 0.65, a quick ratio of 1.50 and a current ratio of 1.93.

Thermo Fisher Scientific (NYSE:TMO - Get Free Report) last announced its earnings results on Wednesday, July 23rd. The medical research company reported $5.36 earnings per share for the quarter, topping analysts' consensus estimates of $5.22 by $0.14. Thermo Fisher Scientific had a net margin of 15.24% and a return on equity of 16.82%. The business had revenue of $10.86 billion during the quarter, compared to the consensus estimate of $10.68 billion. During the same quarter last year, the firm earned $5.37 earnings per share. Thermo Fisher Scientific's quarterly revenue was up 2.9% on a year-over-year basis. Thermo Fisher Scientific has set its Q3 2025 guidance at 5.460-5.510 EPS. FY 2025 guidance at 22.220-22.840 EPS. As a group, equities analysts expect that Thermo Fisher Scientific Inc. will post 23.28 EPS for the current year.

Thermo Fisher Scientific Dividend Announcement

The company also recently announced a quarterly dividend, which will be paid on Wednesday, October 15th. Investors of record on Monday, September 15th will be paid a dividend of $0.43 per share. This represents a $1.72 dividend on an annualized basis and a yield of 0.4%. The ex-dividend date of this dividend is Monday, September 15th. Thermo Fisher Scientific's dividend payout ratio (DPR) is currently 9.95%.

Analysts Set New Price Targets

Several brokerages recently commented on TMO. Hsbc Global Res downgraded shares of Thermo Fisher Scientific from a "strong-buy" rating to a "hold" rating in a research note on Thursday, July 24th. Scotiabank raised shares of Thermo Fisher Scientific from a "sector perform" rating to a "sector outperform" rating and set a $590.00 price objective for the company in a research note on Friday, July 11th. HSBC reissued a "hold" rating and issued a $510.00 price objective on shares of Thermo Fisher Scientific in a research note on Thursday, July 24th. UBS Group raised their price target on shares of Thermo Fisher Scientific from $460.00 to $500.00 and gave the company a "neutral" rating in a research note on Thursday, July 24th. Finally, Barclays raised shares of Thermo Fisher Scientific from an "equal weight" rating to an "overweight" rating and raised their price target for the company from $490.00 to $550.00 in a research note on Thursday, September 11th. Sixteen investment analysts have rated the stock with a Buy rating and five have given a Hold rating to the company. Based on data from MarketBeat.com, the company has an average rating of "Moderate Buy" and a consensus price target of $588.35.

Insider Buying and Selling

In related news, CEO Marc N. Casper sold 10,000 shares of Thermo Fisher Scientific stock in a transaction on Friday, August 22nd. The shares were sold at an average price of $500.96, for a total transaction of $5,009,600.00. Following the completion of the transaction, the chief executive officer owned 115,174 shares of the company's stock, valued at $57,697,567.04. This trade represents a 7.99% decrease in their ownership of the stock. The sale was disclosed in a filing with the Securities & Exchange Commission, which is available at the SEC website. Also, CAO Joseph R. Holmes sold 385 shares of Thermo Fisher Scientific stock in a transaction on Friday, August 29th. The stock was sold at an average price of $492.63, for a total transaction of $189,662.55. Following the transaction, the chief accounting officer directly owned 2,319 shares of the company's stock, valued at $1,142,408.97. This represents a 14.24% decrease in their position. The disclosure for this sale can be found here. Insiders sold 30,066 shares of company stock valued at $14,182,963 over the last quarter. Insiders own 0.33% of the company's stock.

Thermo Fisher Scientific Profile

Thermo Fisher Scientific Inc provides life sciences solutions, analytical instruments, specialty diagnostics, and laboratory products and biopharma services in the North America, Europe, Asia-Pacific, and internationally. The company's Life Sciences Solutions segment offers reagents, instruments, and consumables for biological and medical research, discovery, and production of drugs and vaccines, as well as diagnosis of infections and diseases; and solutions include biosciences, genetic sciences, and bio production to pharmaceutical, biotechnology, agricultural, clinical, healthcare, academic, and government markets.

Want to see what other hedge funds are holding TMO? Visit HoldingsChannel.com to get the latest 13F filings and insider trades for Thermo Fisher Scientific Inc. (NYSE:TMO - Free Report).

This instant news alert was generated by narrative science technology and financial data from MarketBeat in order to provide readers with the fastest and most accurate reporting. This story was reviewed by MarketBeat's editorial team prior to publication. Please send any questions or comments about this story to contact@marketbeat.com.